中华医学会泌尿外科分会机器人学组委员，肾癌研究协作组委员；

中国医师协会泌尿外科分会机器人学组委员；

中国抗癌协会泌尿男生殖肿瘤委员会少见类型肾癌协作组秘书长；

中国医学装备协会腔镜与微创技术分会委员；

四川省医学会泌尿外科学分会青年副主任委员；

四川省肿瘤学会泌尿肿瘤专业委员会委员；

四川省老年医学会泌尿外科专委会委员；

成都市抗癌协会泌尿男生殖系肿瘤委员会候任主任委员

1.Zhenhua Liu, Hao Zeng, Guangxi Sun, et al. Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase-Deficient Renal Cell Carcinoma. Clin Cancer Res. 2024 Jun 3;30(11):2571-2581.

2.Hao Zeng, Pengfei Shen, Zhenhua Liu, et al. The survival benefit of metastasectomy for metastatic non-clear cell renal cell carcinoma: a retrospective cohort study. World J Urol. 2024 Apr 25;42(1):259.

3.Zhenhua Liu, Hao Zeng, Guangxi X Sun, et al. Patients with ASPSCR1-TFE3 fusion achieve better response to ICI based combination therapy among TFE3-rearranged renal cell carcinoma. Mol Cancer. 2024 Jun 26;23(1):132.

4.Yu Shen, Zilin Wang, Zhenhua Liu. A case of renal solid-cystic angiomyolipoma: A case report. Medicine (Baltimore). 2024 Sep 13;103(37):e39631.

5.Yu Shen, Xinyuan Wei, Zhenhua Liu, et al. Association between TyG related indices and insulin resistance in cholelithiasis patients. Asian J Surg. 2024 Sep 10:S1015-9584(24)01970-5.

6.Zhenhua Liu, Ni Chen, Xingming Zhang, et al. Genomic and transcriptomic features between primary and paired metastatic fumarate hydratase-deficient renal cell carcinoma. Genome Med. 2023 May 2;15(1):31.

7.Yang Yang, Qiang Wei, Zhenhua Liu, et al. The multi-omics analyses of acsl1 reveal its translational significance as a tumor microenvironmental and prognostic biomarker in clear cell renal cell carcinoma. Diagn Pathol. 2023 Aug 22;18(1):96.

8.Junjie Zhao, Zhenhua Liu, Hao Zeng, et al. Integrated multi-omics analyses reveal that BCAM is associated with epigenetic modification and tumor microenvironment subtypes of clear cell renal cell carcinoma. Clin Epigenetics. 2022 Aug 8;14(1):99.

9.Zhenhua Liu, Pengfei Shen, Hao Zeng, et al. Integrated exome and RNA sequencing of TFE3-translocation renal cell carcinoma. Nat Commun. 2021 Sep 6;12(1):5262.

10.Liqun Dai, Guohua Shen, Zhenhua Liu, et al. PSMA-targeted melanin-like nanoparticles as a multifunctional nanoplatform for prostate cancer theranostics. J Mater Chem B. 2021 Jan 28;9(4):1151-1161.

11.Zhenhua Liu, Hao Zeng, Pengfei Shen, et al. Efficacy and Safety of Individualized Schedule of Sunitinib by Drug Monitoring in Patients with Metastatic Renal Cell Carcinoma. Cancer Manag Res. 2021 Aug 31:13:6833-6845.

12.Guangxi Sun, Zhenhua Liu, Hao Zeng, et al. Integrated Molecular Characterization of Fumarate Hydratase-deficient Renal Cell Carcinoma. Clin Cancer Res. 2021 Mar 15;27(6):1734-1743.

13.Jindong Dai, Zhenhua Liu, Pengfei Shen, et al. The Prognostic Value of Body Fat Components in Metastasis Renal Cell Carcinoma Patients Treated with TKIs. Cancer Manag Res. 2020 Feb 7:12:891-903.

14.Xingming Zhang, Zhenhua Liu, Pengfei Shen, et al. The influence of dynamic changes in lipid metabolism on survival outcomes in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. Jpn J Clin Oncol. 2020 Dec 16;50(12):1454-1463.

15.Xiang Tu, Zhenhua Liu, Qiang Wei, et al. The Role of 68Ga-PSMA Positron Emission Tomography/Computerized Tomography for Preoperative Lymph Node Staging in Intermediate/High Risk Patients With Prostate Cancer: A Diagnostic Meta-Analysis. Front Oncol. 2020 Aug 18:10:1365.